[1]刘雯洁,莫秋玉,林文远,等.HBV感染并发血小板减少患者外周血中CD4+CD25+调节性T细胞的表达研究[J].现代检验医学杂志,2018,33(04):67-69.[doi:10.3969/j.issn.1671-7414.2018.04.017]
　LIU Wen-jie,MO Qiu-yu,LIN Wen-yuan,et al.Expression of CD4+CD25+ Regulatory T Cells in Peripheral Blood of Patients with Hepatitis B Virus Infection with Thrombocytopenia[J].Journal of Modern Laboratory Medicine,2018,33(04):67-69.[doi:10.3969/j.issn.1671-7414.2018.04.017]
点击复制

HBV感染并发血小板减少患者外周血中CD4+CD25+调节性T细胞的表达研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第33卷
期数:
2018年04期
页码:
67-69
栏目:
论著
出版日期:
2018-08-30

文章信息/Info

Title:
Expression of CD4+CD25+ Regulatory T Cells in Peripheral Blood of Patients with Hepatitis B Virus Infection with Thrombocytopenia
文章编号:
1671-7414(2018)04-067-03
作者:
刘雯洁1; 莫秋玉2; 林文远2; 林 玮1; 卓梅芳1; 刘 源1; 蒋端凤2; 董 敏2
1.桂林医学院,广西桂林 541004; 2.桂林医学院附属医院血液科,广西桂林 541001
Author(s):
LIU Wen-jie1; MO Qiu-yu2; LIN Wen-yuan2; LIN Wei1; ZHUO Mei-fang1;  LIU Yuan1; JIANG Duan-feng2; DONG Min2
1.Guilin MedicalCollege, Guangxi Guilin 541004,China; 2.Department of Hematology, the Affiliated Hospital of Guilin Medical College,Guangxi Guilin 541001,China
关键词:
HBV感染;  血小板减少症;  调节性T细胞;  流式细胞术
分类号:
R512.62; R392.11
DOI:
10.3969/j.issn.1671-7414.2018.04.017
文献标志码:
A
摘要:
目的 探讨CD4+CD25+调节性T细胞与乙肝病毒(HBV)感染并发血小板减少发病的关系及可能机制。方法 收集2017年3～11月在桂林医学院附属医院确诊的12例HBV感染并发免疫性血小板减少症(ITP)患者和同期体检的10例健康个体外周血,分别作为实验组和对照组,应用流式细胞术检测外周血中CD4+/淋巴细胞、CD4+CD25+/淋巴细胞及CD4+CD25+/CD4+比例。结果 实验组与对照组CD4+/淋巴细胞、CD4+CD25+/淋巴细胞、CD4+CD25+/CD4+比例分别为(24.64+9.8)% vs(31.72+6.6)%,(4.05+3.7)% vs(3.61+1.2)%和(14.97+12.0)% vs(11.27+2.8)%,差异均无统计学意义(U=33.0,51.5,55.0,P=0.075,0.575,0.742)。结论 CD4+CD25+调节性T细胞在HBV感染并发血小板减少患者外周血中比例与正常人无明显差异,可能是HBV感染相关免疫耐受与ITP相关免疫调节异常共同作用的结果。
Abstract:
Abstract:Objective To investigate the relationship between CD4+CD25+ regulatory T cells(Tregs)and the pathogenesis of hepatitis Bvirus(HBV)infection with thrombocytopenia and its possible mechanism.Methods Peripheral blood of 12 patients diagnosed as HBV infection with thrombocytopenia and 10 healthy donors at the same time were collected from the Affiliated Hospital of Guilin Medical College from March to November,2017 and classified as experimental and controlled groups respectively.Flowcytometry was used to evaluate the proportion of CD4+/T cells,CD4+CD25+/T cells and CD4+CD25+/CD4+.Results The proportions of CD4+/T cells,CD4+CD25+/T cells and CD4+CD25+/CD4+ in experimental andcontrolled group respectively were[(24.64+9.8)% vs(31.72+6.6)%,U=33.0,P=0.075],[(4.05+3.7)% vs(3.61+1.2)%,U=51.5,P=0.575] and [(14.97+12.0)% vs(11.27+2.8)%,U=55.0,P=0.742] with no statistical significance.Conclusion There was no significant difference between patients of HBV infection with thrombocytopenia and the normal controls in the proportion of CD4+CD25+ regulatory T cells in peripheral blood.Itmay be the result of HBV immune related immune tolerance and immune regulatoryabnormalities associated with immune thrombocytopenia(ITP).

参考文献/References:

[1] Sakaguchi S.Naturally arising CD4+ regulatory T ce-lls for immunologic self-tolerance and negative control of immune responses[J].Ann RevImmunol,2004,22(3):531-562.
[2] 王 彦,王笑蕾.乙型肝炎病毒与血小板减少症的相关性分析[J].中国误诊学杂志,2009,9(22):5395. Wang Y,Wang XL.Correlation analysis between hepatitis B virus andthrombocyopenia[J].Chinese Journal of Misdiagnostics,2009,9(22):5395.
[3] 袁 宏,郝 尧,毛小荣,等.63例慢性肝病合并血小板减少症患者血小板生成素水平及其临床意义[J].国际检验医学杂志,2008,29(11):1036-1037. Yuan H,Hao R,Mao XR,et al.Level of thrombocytopenia in 63 patients with chronic liver disease complicated with thrombocytopenia and its clinicalsignificance[J].International Journal of Laboratory Medicine,2008,29(11):1036-1037.
[4] Pradella P,Bonetto S,Turchetto S,et al.Platelet production and destruction in liver cirrhosis[J].J Hepatol,2011,54(5):894-900.
[5] 郭振兴,季林祥,段毅力,等.干扰素治疗肝炎病毒相关性血小板减少症[J].临床血液学杂志,2008,21(5):229-232. Guo ZX,Ji LX,Duan YL,et al.Interferon alpha for the treatment of patients with hepatitis virus related thrombocytopenia[J].Journal of Clinical Hematology,2008,21(5):229-232.
[6] 崔文娟,朱凤群.慢性乙型肝炎肝硬化血小板减少影响因素的研究进展[J].实用肝脏病杂志,2010,13(1):78-80. Cui WJ,Zhu FQ.Research progress on influencing factors of thrombocytopenia in patients with chronic hepatitis B cirrhosis[J].Journal ClinicalHepatology,2010,13(1):78-80.
[7] 中华医学会血液学分会止血与血栓学组.成人原发免疫性血小板减少症诊断与治疗中国专家共识(2016年版)[J].中华血液学杂志,2016,37(2):89-93. Thrombosis and Hemostasis Group,Hematology Society,Chinese MedicalAssociation.Consensus of Chinese expert on diagnosis and treatment of adult primary immune thrombocytopenia(version 2016)[J].Chinese Journal of Hematology,2016,37(2):89-93.
[8] 中华医学会肝病学分会,中华医学会感染病学分会.慢性乙型肝炎防治指南(2015年更新版)[J].临床肝胆病杂志,2015,31(12):1941-1960. Chinese Society of Hematology and Chinese Society of Infectious Diseases,Chinese Medical Association.The guideline of prevention and treatment forchronic hepatitis B:2015 update version[J].Journal of Clinical Hepatology,2015,31(12):1941-1960.
[9] 李 贝,李从荣.病毒性肝炎血液学变化的研究进展[J].临床血液学杂志,2009,22(7):391-393. Li B,Li CR.Advances in the study hematological changes in viral hepatitis[J].Journal of Clinical Hematology,2009,22(7):391-393.
[10] 沈俊辉,李 宁,范学工.慢性乙型肝炎患者CD4+CD25+Treg细胞的检测及意义[J].世界华人消化杂志,2007,15(26):2790-2795. Shen JH,Li N,Fan XG.Significance of CD4+CD25+regulatory T cells inperipheral blood of chronic hepatitis B patients[J].World Chinese Journal ofDigestology,2007,15(26):2790-2795.
[11] 田 瑛.HBV感染:宿主细胞免疫应答与临床转归[D].北京:中国协和医科大学,2006. Tian Y.HBV infection:Host's cellular response and clinical outcomes[D].Beijing:Peking Union Medical College,2006年.
[12] 孟亚红,孙丽华.CD4+CD25+调节性T细胞在ITP患者中的表达及与临床预后的相关性[J].浙江临床医学,2017,19(3):446-448. Meng YH,Sun LH.Expression of CD4+CD25+regulatory T cells in ITP patients and its correlation with clinical prognosis[J].Zhejiang Clinical MedicalJournal,2017,19(3):446-448.
[13] 郭小嫚,李建厂.CD4+CD25+调节性T细胞在免疫性血小板减少性紫癜发病机制中的作用[J].国际儿科学杂志,2016,43(8):622-625. Guo XM,Li JC.CD4+CD25+ regulatory T lymphocytes in the role of the pathogenesis of immune thrombocytopenic purppura[J].International Journal of Pediatrics,2016,43(8):622-625.
[14] 肖影群,黄 波,陈川英,等.抗病毒治疗对慢性乙肝患者的CD4+CD25+Foxp3+调节T细胞的影响及其临床病理意义[C].贵阳全国免疫学学术大会分会场交流报告,2015. Xiao YQ,Huang B,Chen CY,et al.Effect of antiviral therapy on CD4+CD25+Foxp3+ regulatory T cells in patients with chronic hepatitis B and its clinicopathological significance[C].Exchange Report of the National Conference on Immunology,2015.
[15] 赵海丰,张翼鷟.CD4+CD25+调节性T细胞在免疫性血小板减少症发病中的研究进展[J].天津医药,2014,42(4):390-392. Zhao HF,Zhang YZ.Recent research in role of C D4+CD25+ regulatory T cell in pathogenesis of immune thrombocytopenia[J].Tianjin Medical Journal,2014,42(4):390-392.
[16] 闫 莉,邵宗鸿.调节性T细胞体外扩增和免疫治疗研究进展[J].中国实验血液学杂志,2015,23(2):562-567. Yan L,Shao ZH.Advances in ex vivo expansion and immunotherapy application of regulatory T cells[J].Journal of Experimental Hematology,2015,23(2):562-567.

备注/Memo

备注/Memo:
基金项目:广西高校中青年基础能力提升项目(KY2016YB309),广西壮族自治区教育厅课题(YB2014286),国家级大学生创新创业训练计划项目(201610601029)。 作者简介:刘雯洁(1995-),女,本科,主要从事自身免疫研究,E-mail:533966607@qq.com。 莫秋玉(1989-),女,在读硕士研究生,主要从事血小板减少研究,E-mail:770562381@qq.com,共同第一作者。 通讯作者:蒋端凤(1986-),男,硕士,主治医师,E-mail:duanfeng989949@126.com。 董 敏(1972-),女,博士,教授,硕士研究生导师,E-mail:dm1175@sina.com,共同通讯作者。
更新日期/Last Update: 2018-08-16